reports
Scheme of arrangement becoming effective
Scheme of arrangement becoming effective Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 9 June 2022, 1.00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Scheme becomi...
Court Sanction of the Scheme of Arrangement
Court Sanction of the Scheme of Arrangement Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 June 2022, [1.00] p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under ...
Acacia Pharma Results of the Court Meeting and the General Meeting hel...
Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022 Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 20 May 2022, 8:00 a.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected b...
Publication of Annual Report and Financial Statements for the Year end...
Publication of Annual Report and Financial Statements for the Year ended 31 December 2021 This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer ...
Publication of Scheme Document
Publication of Scheme Document Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 27 April 2022, 12:00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Publication of Schem...
Acacia Pharma Group plc - Total Number of Voting Rights and Capital
Acacia Pharma Group plc - Total Number of Voting Rights and Capital THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law) Cambridge, UK and Indianapolis, US – 31 March 2022, 18:00 CET. As previously announced1, Acacia Pharma Group plc issued ordinary shares to its Employee Benefit Trust within the authorised capital. The gross amount of this capital increase amounted to GBP 1,274,20 via an issue of 63,710 new shares at an issue price of GBP 0.02 per share. The shares were issued to satisfy the vesting of ...
Acacia Pharma to Postpone Publication of its Results for the Full Year...
Acacia Pharma to Postpone Publication of its Results for the Full Year 2021, Scheduled on 31 March 2022 THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction For immediate release 30 March 2022, 6:00 p.m. (Brussels time) Cambridge, UK and Indianapolis, US – Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), announces that it will not p...
Offer by Eagle Pharmaceuticals, Inc.
Offer by Eagle Pharmaceuticals, Inc. ACACIA PHARMA GROUP PLC PROPOSED TRANSACTION WITH EAGLE PHARMACEUTICALS, INC. THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION AND INSIDE INFORMATION Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction For immediate release 28 March 2022, 08:00 a.m. (Brussels time) RECOMMENDED SCHEME OF ARRANGEMENT of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a Sc...
Acacia Pharma Announces Chief Financial Officer Gary Gemignani is to L...
Acacia Pharma Announces Chief Financial Officer Gary Gemignani is to Leave the Company This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 23 March 2022: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Ch...
Issue of Shares to Employee Benefit Trust
Issue of Shares to Employee Benefit Trust This announcement contains regulated information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15 March 2022: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, was notified on 11 March 2022 that the Compa...
Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust
Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law) Acacia Pharma Group plc As previously announced1, Acacia Pharma Group plc issued ordinary shares to its Employee Benefit Trust within the authorised capital. The gross amount of this capital increase amounted to GBP 22,909.44 via an issue of 1,145,472 new shares at an issue price of GBP 0.02 per share. The shares were issued to satisfy the vesting of share awards granted under the Com...
Correction: Issue of Shares to Employee Benefit Trust
Correction: Issue of Shares to Employee Benefit Trust Correction – Admission Date for New Ordinary Shares Included This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive p...
Issue of Shares to Employee Benefit Trust
Issue of Shares to Employee Benefit Trust This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, was notified on 14 December 2021 that the ...
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-appro...
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 December 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive proce...
Acacia Pharma to Present at the Jefferies London Healthcare Conference
Acacia Pharma to Present at the Jefferies London Healthcare Conference Cambridge, UK and Indianapolis, US – 10 November 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), is pleased to announce that its Chief Executive Officer, Mike Bolinder will present at the Jefferies London Healthcare Conference 2021 on Tuesday, 16 November 2021. The presentation will begin at 09:20 GMT / 10.20 CET and a live video webcast will be available to registered conference attendees. The link to the webcast is available . A replay will also be available to regi...
Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and...
Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Group plc Barhemsys® and Byfavo® launches continue to show strong progress gaining formulary access in 107 additional accounts over the past 3 monthsFor Barhemsys – 260 accounts on formulary with >80% win rate to date and well on track to meet annual formulary goal (300 accounts) by year endFor Byfavo – ...
Acacia Pharma Announces Submission and Validation of Marketing Authori...
Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 September 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as su...
Correction: Notice of Results
Correction: Notice of Results Correction for date of KOL webcast Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 Conference Call to be held on 30 September at 14.00 CEST/08.00 EST Cambridge, UK and Indianapolis, US – 23 September 2021, 13:00 CEST: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,...
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pedi...
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 September 2021: 07:00 CET Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures o...
Acacia Pharma to Host Webinar with Key Opinion Leaders to Discuss the ...
Acacia Pharma to Host Webinar with Key Opinion Leaders to Discuss the Hospital User Experience with Barhemsys® and Byfavo® Cambridge, UK and Indianapolis, US – 2 September 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), is pleased to announce that it will be hosting a webinar at 18:00hrs CEST / 12:00pm EDT on Thursday 30 September 2021 entitled “Hospital User Experience with Barhemsys® and Byfavo®.” The webinar will feature presentations by Key Opinion Leaders (KOLs) Tong Joo (TJ) Gan, MD, MBA, MHS, FRCA (UK), FRCA (Ire), LicAc (Stony Bro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.